Results 51 to 60 of about 18,054 (201)

Luminescent multiplex viability assay for Trypanosoma brucei gambiense [PDF]

Parasites & Vectors, 2013
New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to
Stijn Rogé, Nick Van Reet, Pati Pyana, Philippe Büscher, Filip Claes   +4 more
openaire   +3 more sources

Retrospective clinical performance evaluation of the Abbott Bioline HAT 2.0, a rapid diagnostic test for human African trypanosomiasis based on recombinant antigens. [PDF]

Trop Med Int Health
Abstract Background Rapid diagnostic tests for the serological detection of gambiense human African trypanosomiasis (gHAT) have been developed to overcome the limitations of the traditional screening method, CATT/T. b. gambiense. The Abbott Bioline human African trypanosomiasis (HAT) 2.0 rapid diagnostic test has recently been developed by Abbott using
Tablado Alonso S, Biéler S, Inocêncio da Luz R, Verlé P, Büscher P, Hasker E.   +5 more
europepmc   +2 more sources

Wild chimpanzees are infected by Trypanosoma brucei

International Journal for Parasitology: Parasites and Wildlife, 2015
Although wild chimpanzees and other African great apes live in regions endemic for African sleeping sickness, very little is known about their trypanosome infections, mainly due to major difficulties in obtaining their blood samples.
Milan Jirků, Jan Votýpka, Klára J. Petrželková, Kateřina Jirků-Pomajbíková, Eva Kriegová, Roman Vodička, Felix Lankester, Siv Aina J. Leendertz, Roman M. Wittig, Christophe Boesch, David Modrý, Francisco J. Ayala, Fabian H. Leendertz, Julius Lukeš   +13 more
doaj   +1 more source

In silico analysis of the HSP90 chaperone system from the African trypanosome, Trypanosoma brucei

Frontiers in Molecular Biosciences, 2022
African trypanosomiasis is a neglected tropical disease caused by Trypanosoma brucei (T. brucei) and spread by the tsetse fly in sub-Saharan Africa. The trypanosome relies on heat shock proteins for survival in the insect vector and mammalian host.
Miebaka Jamabo, Stephen John Bentley, Paula Macucule-Tinga, Praise Tembo, Adrienne Lesley Edkins, Aileen Boshoff   +5 more
doaj   +1 more source

Chimerization at the AQP2–AQP3 locus is the genetic basis of melarsoprol–pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates

International Journal for Parasitology: Drugs and Drug Resistance, 2015
Aquaglyceroporin-2 is a known determinant of melarsoprol–pentamidine cross-resistance in Trypanosoma brucei brucei laboratory strains. Recently, chimerization at the AQP2–AQP3 tandem locus was described from melarsoprol–pentamidine cross-resistant ...
Fabrice E. Graf, Nicola Baker, Jane C. Munday, Harry P. de Koning, David Horn, Pascal Mäser   +5 more
doaj   +1 more source

Whole-Genome Sequencing of Trypanosoma brucei Reveals Introgression between Subspecies That Is Associated with Virulence

mBio, 2013
Human African trypanosomiasis is caused by two subspecies of Trypanosoma brucei. Trypanosoma brucei rhodesiense is found in East Africa and frequently causes acute disease, while Trypanosoma brucei gambiense is found in West Africa and is associated with
Ian Goodhead, Paul Capewell, J. Wendi Bailey, Tanja Beament, Michael Chance, Suzanne Kay, Sarah Forrester, Annette MacLeod, Mark Taylor, Harry Noyes, Neil Hall   +10 more
doaj   +1 more source

Overproduction and Characterization of Recombinant Soluble <i>Trypanosoma brucei</i> Phospholipase A₂. [PDF]

Eng Life Sci
ABSTRACT Trypanosoma brucei phospholipase A2 (TbPLA2) is a validated drug target but the difficulty in expressing its soluble recombinant protein has limited its exploitation for drug and vaccine development for African and American trypanosomiases. We utilized recombinant deoxyribonucleic acid (DNA) technology approaches to express soluble TbPLA2 in ...
Adepoju OA, Quinnell D, Sirohi H, Amlabu E, Sallau AB, Ibrahim A, Atawodi SE, Shuaibu MN, Chang G, Balogun EO.   +9 more
europepmc   +2 more sources

Free-ranging pigs identified as a multi-reservoir of Trypanosoma brucei and Trypanosoma congolense in the Vavoua area, a historical sleeping sickness focus of Côte d'Ivoire.

PLoS Neglected Tropical Diseases, 2021
BackgroundThe existence of an animal reservoir of Trypanosoma brucei gambiense (T. b. gambiense), the agent of human African trypanosomiasis (HAT), may compromise the interruption of transmission targeted by World Health Organization.
Barkissa Mélika Traoré, Mathurin Koffi, Martial Kassi N'Djetchi, Dramane Kaba, Jacques Kaboré, Hamidou Ilboudo, Bernadin Ahouty Ahouty, Minayégninrin Koné, Bamoro Coulibaly, Thomas Konan, Adeline Segard, Lingué Kouakou, Thierry De Meeûs, Sophie Ravel, Philippe Solano, Jean-Mathieu Bart, Vincent Jamonneau   +16 more
doaj   +1 more source

Human and animal Trypanosomes in Côte d'Ivoire form a single breeding population.

PLoS ONE, 2013
BackgroundTrypanosoma brucei is the causative agent of African Sleeping Sickness in humans and contributes to the related veterinary disease, Nagana. T. brucei is segregated into three subspecies based on host specificity, geography and pathology. T.
Paul Capewell, Anneli Cooper, Craig W Duffy, Andy Tait, C Michael R Turner, Wendy Gibson, Dieter Mehlitz, Annette Macleod   +7 more
doaj   +1 more source

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

Parasites & Vectors, 2018
BackgroundWhile the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of choice when this trial commenced ...
Freddie Kansiime, Seraphine Adibaku, C. Wamboga, F. Idi, C. Kato, L. Yamuah, M. Vaillant, D. Kioy, P. Olliaro, E. Matovu   +9 more
semanticscholar   +2 more sources